Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
AbbVie Posts Q3 Revenue Beat and Record Highs on Drug Growth
AbbVie's ongoing execution past patent cliffs highlights cash-flow resilience for pharmaceutical equity investors.
Based on reporting from yahoo-tickers-tape-movers.
AbbVie shares reached record highs following third-quarter results showing $17.4 billion in revenue and an adjusted EPS beat. The pharmaceutical firm successfully moved past the loss of exclusivity on Humira behind strong growth engines like Skyrizi and Rinvoq.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
AbbVie·$ABBV$ABBVAbbVie
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/ABBV. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
### Session Tape — AbbVie (ABBV) +1.41%
## Catalyst Analysis: Q3 Earnings Beat and Guidance Raise AbbVie posted third-quarter revenue of $17.4 billion, marking a 10.3% increase from a year earlier. Adjusted earnings per share came in at $3.82, beating management guidance by approximately $0.07 and more than doubling the $1.86 per share reported in the prior-year period. Growth was anchored by key pharmaceutical lines, including Skyrizi revenue jumping 22.7% to $5.78 billion and Rinvoq sales climbing 23.9% to $2.71 billion. Together, these therapies generated $8.5 billion in revenue, accounting for 48.7% of total revenue. Alongside the print, management announced a 5.2% dividend increase, pushing the quarterly payout to $1.64 per share and continuing a multi-year capital return trajectory since the original spinoff.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
AbbVie's ongoing execution past patent cliffs highlights cash-flow resil
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: October 31, 2026 at 11:01 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
pharmaceutical patent cliff navigation
AbbVie made record highs because its new medicines are selling very well and making up for older drugs losing their patent protection. Investors care because it proves big pharmaceutical companies can keep making money even as their older products get copied.
What changed
AbbVie posted a Q3 revenue and earnings beat alongside a dividend increase, proving new blockbusters successfully offset older patent losses.
Who wins / who loses
New blockbuster drug makers win against single-product biotechs facing patent cliffs.
Time horizon
Think in terms of the next few months.
Confidence & best fit
high confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $ABBVBuild slowly — only if it fits your plan
AbbVie is the main company in this story, and its new drugs are selling so well that its stock is hitting record highs.
View $ABBV chart → · End-of-day delayed data
Peer
- $LLYWatch — track, don’t rush
Eli Lilly is a similar giant drug maker that also relies on popular new medicines to grow.
View $LLY chart → · End-of-day delayed data
Second-order
- $PFEStay away — for now
Pfizer is another big drug company, but it hasn't had the same easy time replacing its old medicines.
View $PFE chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Direction: bullish · Style: Covered-call income (only if you already own shares) · Level: intermediate
Beginners should skip options and just buy the stock, as options can be complex and risky.
Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research regional contract research organizations (CROs) supporting pharmaceutical clinical trials for Skyrizi and Rinvoq expansions.
What would break this thesis
- Unexpected regulatory delays or safety issues for Skyrizi or Rinvoq expansion trials.
- A broader macroeconomic downturn causing a sharp contraction in healthcare spending and prescription volumes.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).